Holen Sie sich die Stockscreener-App
20.07
1.32%
0.2424
Schlusskurs vom Vortag:
$19.83
Offen:
$19.97
24-Stunden-Volumen:
340.97K
Relative Volume:
0.86
Marktkapitalisierung:
$921.80M
Einnahmen:
$723.31M
Nettoeinkommen (Verlust:
$111.63M
KGV:
8.9001
EPS:
2.2553
Netto-Cashflow:
$111.01M
1W Leistung:
-28.16%
1M Leistung:
-29.77%
6M Leistung:
-31.17%
1J Leistung:
-27.25%
1-Tages-Spanne:
$19.56
$20.15
1-Wochen-Bereich:
$19.56
$28.17
52-Wochen-Spanne:
$19.56
$31.26
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Firmenname
Amphastar Pharmaceuticals Inc
Sektor
Telefon
909-980-9484
Adresse
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
20.06 | 911.23M | 723.31M | 111.63M | 111.01M | 2.2553 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.21 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.81 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.46 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.44 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
487.53 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-08-12 | Hochstufung | Needham | Hold → Buy |
| 2025-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-03-05 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-17 | Eingeleitet | BofA Securities | Neutral |
| 2023-07-25 | Fortgesetzt | Jefferies | Buy |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-07-29 | Eingeleitet | CapitalOne | Overweight |
| 2022-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | Eingeleitet | Northland Capital | Outperform |
| 2019-03-13 | Herabstufung | Needham | Buy → Hold |
| 2019-03-13 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-03-13 | Bestätigt | Needham | Buy |
| 2017-12-01 | Bestätigt | Needham | Buy |
| 2017-11-09 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | Bestätigt | Needham | Buy |
| 2017-03-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-05-10 | Bestätigt | Needham | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2015-06-19 | Bestätigt | Needham | Buy |
| 2015-06-03 | Eingeleitet | Raymond James | Strong Buy |
| 2014-07-21 | Eingeleitet | Needham | Buy |
Alle ansehen
Amphastar Pharmaceuticals Inc Aktie (AMPH) Neueste Nachrichten
Royce & Associates LP Raises Stock Holdings in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals to Present at the Barclays 28th Annual Global Healthcare Conference - ACCESS Newswire
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Potential Upside of 38% Attracts Investor Attention - DirectorsTalk Interviews
Wells Fargo Sees Amphastar Pharmaceuticals, Inc.'s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth - Finviz
Wells Fargo Sees Amphastar Pharmaceuticals, Inc.’s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth - Yahoo Finance
Cash per share of Amphastar Pharmaceuticals, Inc. – DUS:29A - TradingView
Amphastar FDA Wins And Pipeline Expansion Contrast With Weak Earnings And Valuation - Yahoo Finance
Amphastar: Higher Costs, Lower Growth, And A 'Value Trap' Label (NASDAQ:AMPH) - Seeking Alpha
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2025 Earnings Call Transcript - Insider Monkey
Amphastar Pharmaceuticals Stock Hits New 12-Month Low After Analyst Downgrade - National Today
AMPH Stock (-24%): Q4 Earnings Miss Sparks Aggressive Liquidation - Trefis
Amphastar Pharmaceuticals Q4 2025 Report: Revenue Miss, Stock DeclineNews and Statistics - IndexBox
Amphastar Pharmaceuticals (NASDAQ:AMPH) Hits New 12-Month Low After Analyst Downgrade - MarketBeat
Amphastar stock hits 52-week low at $20.38 By Investing.com - Investing.com Australia
Amphastar Pharmaceuticals (NASDAQ:AMPH) Issues Quarterly Earnings Results - MarketBeat
Amphastar Pharmaceuticals Inc (29A.BE) Stock Price, News, Quote & History - Yahoo Finance
Amphastar stock hits 52-week low at $20.38 - Investing.com
Why Amphastar Pharmaceuticals (AMPH) Shares Are Plunging Today - Finviz
Wells Fargo & Company Has Lowered Expectations for Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Down Following Analyst Downgrade - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Lowered to $30.00 at Needham & Company LLC - MarketBeat
Amphastar Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham cuts Amphastar stock price target on Q4 miss, weak sales - Investing.com
TD Asset Management Inc Sells 103,038 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Amphastar Stock Pre-Market (-15%): Q4 Earnings and Revenue Miss - Trefis
Amphastar Pharmaceuticals (AMPH) Margin Compression Reinforces Bearish Narratives Despite Low 9.5x P/E - Sahm
Amphastar Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Compared to Estimates, Amphastar (AMPH) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Amphastar Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Earnings call transcript: Amphastar’s Q4 2025 Misses Estimates, Stock Dips By Investing.com - Investing.com Canada
Amphastar (AMPH) Q4 2025 Earnings Call Transcript - AOL.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 CY2025 Revenue Estimates, Stock Drops 11.7% - Finviz
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates - Yahoo Finance
Amphastar Pharmaceuticals Inc. (AMPH) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Amphastar Pharmaceuticals Inc. (AMPH) stock falls on Q4 2025 Earnings - Quiver Quantitative
Amphastar Pharmaceuticals Reports Financial Results for Q4 and Full Year 2025 - TradingView
Earnings Flash (AMPH) Amphastar Pharmaceuticals, Inc. Reports Q4 Revenue $183.1M, vs. FactSet Est of $190.1M - marketscreener.com
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025 - ACCESS Newswire
Amphastar Pharmaceuticals Q4 2025 Earnings: Release Date & Analyst OutlookNews and Statistics - IndexBox
Amphastar earnings on deck: Can pipeline offset flat growth? By Investing.com - Investing.com UK
Amphastar: Fourth Quarter Financial Overview - Bitget
Insights Ahead: Amphastar Pharma's Quarterly Earnings - Benzinga
Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect - Yahoo Finance UK
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring a 14.60% Potential Upside - DirectorsTalk Interviews
Amphastar Announces FDA Approval for Ipratropium Bromide HFA - ACCESS Newswire
FDA clears Amphastar rival to Atrovent inhaler, 180-day exclusivity - Stock Titan
(AMPH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Aug Reactions: Will Amphastar Pharmaceuticals Inc outperform the market in YEARWeekly Risk Report & Weekly Stock Breakout Alerts - baoquankhu1.vn
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026 - galvnews.com
Amphastar schedules Feb. 26 call on Q4 2025 financials after market close - Stock Titan
Finanzdaten der Amphastar Pharmaceuticals Inc-Aktie (AMPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amphastar Pharmaceuticals Inc-Aktie (AMPH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 17 '25 |
Sale |
26.20 |
9,787 |
256,379 |
138,043 |
| Petersen Floyd F. | Director |
Dec 12 '25 |
Sale |
25.92 |
2,426 |
62,888 |
71,368 |
| Petersen Floyd F. | Director |
Dec 11 '25 |
Sale |
25.69 |
1,737 |
44,620 |
73,794 |
0.47%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):